Spots Global Cancer Trial Database for leukemia, myelocytic, acute
Every month we try and update this database with for leukemia, myelocytic, acute cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Use of the MiCK Assay for Apoptosis in AML | NCT00286845 | Leukemia, Myelo... | Standard Chemot... | 18 Years - | Pierian Biosciences | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) | NCT00201240 | Leukemia, Myelo... | CD34+ selection... | 18 Years - 65 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | NCT00406393 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic... | Tacrolimus Methotrexate Sirolimus | 2 Years - 60 Years | Medical College of Wisconsin | |
| Trial to Reduce Alloimmunization to Platelets (TRAP) | NCT00000589 | Blood Platelets Hematologic Dis... Immunization Leukemia, Myelo... Blood Transfusi... | platelet transf... | 15 Years - 75 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia | NCT01756118 | Acute Lymphobla... Leukemia, Myelo... Chronic Myeloge... | BEZ235 | 18 Years - | Goethe University | |
| Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission | NCT00186381 | Leukemia, Myelo... Leukemia Blood and Marro... | high dose chemo... | 16 Years - 69 Years | Stanford University | |
| Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | NCT00962767 | Leukemia, Myelo... | gemtuzumab ozog... ATRA plus 6-MP ... | 18 Years - 61 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) | NCT00201240 | Leukemia, Myelo... | CD34+ selection... | 18 Years - 65 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes | NCT00048100 | Leukemia, Myelo... | Apheresis Stem Cell Trans... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML | NCT02140242 | Leukemia, Myelo... | study part 1 - ... induction cycle... | 18 Years - 65 Years | Technische Universität Dresden | |
| Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission | NCT00186381 | Leukemia, Myelo... Leukemia Blood and Marro... | high dose chemo... | 16 Years - 69 Years | Stanford University | |
| Trial to Reduce Alloimmunization to Platelets (TRAP) | NCT00000589 | Blood Platelets Hematologic Dis... Immunization Leukemia, Myelo... Blood Transfusi... | platelet transf... | 15 Years - 75 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | NCT00962767 | Leukemia, Myelo... | gemtuzumab ozog... ATRA plus 6-MP ... | 18 Years - 61 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) | NCT00201240 | Leukemia, Myelo... | CD34+ selection... | 18 Years - 65 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) | NCT01723657 | Leukemia, Myelo... | Ara-C Autologous peri... Allogeneic matc... G-CSF CD34+ selection... Mylotarg purgin... | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | NCT00393380 | Leukemia, Myelo... Anemia, Aplasti... Myelofibrosis Lymphoma Hodgkin Disease Leukemia, Lymph... Leukemia, Myelo... Leukemia, Lymph... | Parathyroid Hor... | 18 Years - 45 Years | The Emmes Company, LLC | |
| Infection and Tumour Antigen Cellular Therapy | NCT02895412 | Leukemia, Myelo... | Donor-derived W... | 1 Year - 70 Years | University of Sydney | |
| Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML | NCT02140242 | Leukemia, Myelo... | study part 1 - ... induction cycle... | 18 Years - 65 Years | Technische Universität Dresden | |
| AML Treatment in Untreated Adult Patients | NCT00449319 | Leukemia, Myelo... | Identification ... Daunorubicine Transplant | 15 Years - 61 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia | NCT00304447 | Leukemia, Myelo... Infusions, Intr... | Mylotarg | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Risk-adapted Therapy for Adult Acute Myeloid Leukemia. | NCT01716793 | Leukemia, Myelo... | Ara-C Autologous tran... Allogeneic HLA-... CD34+ selection | 18 Years - 60 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) | NCT01339910 | Leukemia, Myelo... | Fludarabine and... Fludarabine and... Busulfan and Fl... Busulfan and Cy... Cyclophosphamid... | 18 Years - 65 Years | Medical College of Wisconsin | |
| Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia | NCT00152594 | Leukemia, Myelo... | voriconazole | 18 Years - | University of Cologne | |
| Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) | NCT00126321 | Leukemia, Myelo... | cladribine | 18 Years - | University Hospital, Bonn | |
| AML Treatment in Untreated Adult Patients | NCT00449319 | Leukemia, Myelo... | Identification ... Daunorubicine Transplant | 15 Years - 61 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia | NCT00152594 | Leukemia, Myelo... | voriconazole | 18 Years - | University of Cologne |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
